mitochondrial ribosomal protein L20Genealiases: L20mt · MRP-L20 · bL20m
Q-omics provides the consensus-scored MRPL20 profile across patient tissues and cancer cell-line models. MRPL20 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MRPL20 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, MRPL20 protein abundance shows 18,560 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, and LSCC as cancer lineages where MRPL20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL20 survival associations across molecular data types. MRPL20 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL20 RNA expression–survival associations across cancer types. High MRPL20 expression shows unfavorable associations in KICH, UCEC, LGG, ACC and HNSC, but favorable associations in OV. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MRPL20 RNA expression.
This table summarizes MRPL20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL20 shows lower tumor expression in KICH and KIRP and higher tumor expression in LIHC, BRCA, COAD and STAD. The KICH box plot shows higher MRPL20 RNA expression in normal versus tumor tissue (log2 FC = −1.325, t-test p < 0.001).
This table shows molecular features associated with MRPL20 in patient tissues and cancer cell lines. In patient samples, MRPL20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
